NCT00602498已完成不适用
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was the bioequivalence of a potential generic 500 mg clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin tablet, Biaxin® following a single 500 mg dose, administered with food.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to clarithromycin or any other macrolide antibiotic.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, Two period, Seven day washout
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Clarithromycin Tablets Under Fasting ConditionsInfectionNCT00601315Roxane Laboratories40
已完成
1 期
Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.HealthyNCT00840216Teva Pharmaceuticals USA22
已完成
1 期
Clarithromycin 500 mg Extended Release Tablets Under Fasting ConditionsHealthyNCT00840411Teva Pharmaceuticals USA66
已完成
1 期
Comparative Bioavailability Study of Clarithromycin 250 mg TabletsHealthyNCT00648830Mylan Pharmaceuticals Inc32
已完成
1 期
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting StateHealthyNCT00648960Mylan Pharmaceuticals Inc64